Introduction {#S0001}
============

Many studies have revealed an important role for the abnormal activation of the inflammatory reaction in the development of T2DM and its macrovascular or microvascular complications.[@CIT0001]--[@CIT0003] Interleukins, including IL-6, IL-1β, and IL-2 are important inflammatory factors. IL-6 suppresses the insulin signaling pathway by activating suppressor of cytokine signaling-3 (SOCS-3) and c-Jun N-terminal kinase (JNK), causes endothelial cell dysfunction and promotes the development of chronic micro- and macrovascular complications by stimulating monocyte chemotactic protein-1 and cell adhesion molecules.[@CIT0004] IL-1β is mainly regulated by diet-induced metabolic stress. Its binding to interleukin-1 receptor type I (IL-1RI) reduces the expression of insulin receptor substrate-1 (IRS-1), leads to islet cell damage and reduces the sensitivity of peripheral tissues to insulin.[@CIT0005] IL-1β is related to retinal dysfunction in subjects with T2DM.[@CIT0006] IL-2 is mainly secreted by Helper T Lymphocyte(TH) after antigen or mitogen stimulation and induces IL-1 secretion. Changes in the IL-2 signaling pathway have been reported to cause Treg dysfunction in subjects with T2DM.[@CIT0007] In addition, tumor necrosis factor-α (TNF-α), an adipocytokine, has been reported to induce T2DM by activating nuclear factor kappa-B (NF-κB), Jun NH~2~-terminal kinase (JNK) and other pathways, and may contribute to the development and progression of renal injury in individuals with T2DM.[@CIT0008] Ferritin is an index of the iron stores in the body. High ferritin levels are associated with chronic inflammation, which might cause metabolic disorder, including islet beta cell dysfunction and insulin resistance.[@CIT0009]

Several hypoglycemic agents have been reported to ameliorate chronic inflammation and protect vessels in patients with T2DM. Metformin is a commonly used basic hypoglycemic agent, and its anti-inflammatory effects have been confirmed in numerous studies. Andrews M, et al observed had lower levels of C-reactive protein (CRP) and TNF-α in obese patients with diabetes who were treated with metformin. However, no differences in the glucose levels or lipid profiles were observed.[@CIT0010] A randomized, placebo-controlled trial showed significantly reduced CRP levels in 390 patients with T2DM after treatment with metformin; these patients were followed for 4.3 years.[@CIT0011] In these studies, the effects of metformin on IL-6, IL-1β, IL-2 and ferritin levels were not observed. However, the effect of metformin on vascular complications remains uncertain.[@CIT0012],[@CIT0013] Acarbose, an α-glycosidase inhibitor, is commonly used to treat Chinese patients with diabetes. Acarbose significantly decreases glucose and lipid levels and influences gastrointestinal functions.[@CIT0014] However, only one study showed that acarbose reduced IL-6 and CRP levels in patients with T2DM after 7 months of treatment compared with a placebo.[@CIT0015] Subgroup analyses in the STOP-NIDDM trial showed that acarbose administration reduces the intima media thickness and the risk of cardiovascular disease.[@CIT0016],[@CIT0017]

In this prospective randomized controlled trial, we studied the effects of metformin and acarbose on the levels of the inflammatory factors IL-6, TNF-α, IL-1β, IL-2 and ferritin in patients with newly diagnosed T2DM to determine whether these two anti-hyperglycemic agents improve the chronic inflammatory state, a definite risk factor for diabetic complications.

Study design {#S0002}
============

Subjects {#S0002-S2001}
--------

Newly diagnosed T2DM group (T2DM): Seventy patients were recruited from the outpatient department of West China Hospital, which is a MARCH research site.[@CIT0018],[@CIT0019] The first subject was recruited to our study on December the first, 2008. All patients were diagnosed with T2DM within 6 months and were not treated with any hypoglycemic agent. The average patient age ranged from 30 to 70 years, and the average BMI ranged from 19 to 30 kg/m^2^. The A1C level ranged from 7.0% to 10%, and the FPG level was ≤11.1 mmol/L. None of the subjects had an infection during the two weeks prior to the study, liver or kidney diseases, severe cardiovascular and hematological system diseases, and other endocrine or mental system diseases.

Normal control (NC) group: Thirty-two healthy volunteers with normal glucose tolerance were recruited.

Methods {#S0002-S2002}
-------

After 4 weeks of lifestyle therapy administered according to Chinese diabetes management guidelines, all patients with newly diagnosed T2DM completed a standard meal test (70 g of instant noodles equivalent to 500 kilocalories of energy intake). Blood was collected at 0, 1/2 and 2 hrs after the standard meal. Then, patients in the T2DM group were randomly assigned (1:1) to the metformin-treated subgroup, which was administered 1500 mg of metformin once daily (500 mg per tablet, Beijing Double Crane Pharms, Beijing, China) or the acarbose-treated subgroup, which was administered 300 mg of acarbose once daily (50 mg per tablet, Bayer Healthcare, Beijing, China). Acarbose was initially administered at a dose of 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner during the second week, 50 mg three times a day at three meals during the third week, and 100 mg three times a day from the fourth week onward. Metformin was initially administered at a dose of 500 mg once a day after dinner during the first 2 weeks and titrated up to 1000 mg once a day after dinner during the third week and 1500 mg once a day after dinner from the fourth week onward. The T2DM group was scheduled for follow-up every 2 weeks during the first 4 weeks and then every 4 weeks thereafter.

The height, weight, waist circumference, hip circumference, and blood glucose, insulin, A1C, TG, TC, HDL-C, LDL-C, IL-6, TNF-α, IL-1β, IL-2 and ferritin levels were measured at baseline, 24 weeks, and 48 weeks after treatment. The blood glucose, insulin, A1C, TG, TC, HDL-C, LDL-C, IL-6, TNF-α, IL-1β, IL-2 and ferritin levels were detected using standard laboratory procedures. Glucose was measured using the glucose oxidase method, insulin was measured using a radioimmunoassay, TG and TC were measured using enzymatic methods, and HDL-C and LDL-C were measured using the phosphor-tungstic acid precipitation method. IL-6, TNF-α, IL-2, and IL-1β were measured using enzyme immunoassay kits (R&D systems, Minneapolis, minn), and ferritin was measured using a radioimmunoassay kit (Beijing Research Institute of biotechnology of the North, Beijing, China).

Statistical analyses {#S0002-S2003}
--------------------

The datasets analyzed during the current study are available from the corresponding author on reasonable request within ten years of the publication. The data were analyzed using Excel and presented as means ± standard deviations. An independent samples *t*-test or variance-covariance analysis was used to compare the data between the two subgroups. A paired *t*-test was used to compare the pre- and post-treatment data in the same subgroup. All *P-*values were two-tailed, and *P*\<0.05 was considered statistically significant. All statistical analyses mentioned above were performed using SPSS version 25.0 for Windows software.

Compliance with ethical guidelines {#S0002-S2004}
----------------------------------

This study's design was approved by the Medical ethics committee of West China Hospital of Sichuan university. All procedures performed in the study were conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants who were included in the study.

Results {#S0003}
=======

Comparison of the biochemical parameters of the T2DM and NC groups {#S0003-S2001}
------------------------------------------------------------------

The average age was comparable between the two groups, while the sex distribution, BMI and WHR significantly differed between the two groups (*P*\<0.05). After adjusting for sex, BMI and WHR, the levels of the 0 hr, 1/2 hr and 2 hr glucose, A1C, TG, TC, and LDL-C in the T2DM group were significantly higher than those in the NC group (*P*\<0.05); 1/2 hr and 2 hr insulin levels were detected in the T2DM group than in the NC group (*P*\<0.05). After adjusting for sex, BMI and WHR, the levels of TG, TC and LDL-C levels, IL-6, TNF-α, IL-2 and ferritin in the T2DM group were higher than in the NC group (*P*\<0.05), but IL-1β levels were comparable between the two groups ([Table 1](#T0001){ref-type="table"}).Table 1Comparison of the baseline parameters of the T2DM and NC groupsParametersNC group (n=32)T2DM group (n=70)Sex (males/females)13/1945/25\*Age (years)52.41±8.5751.31±9.25BMI (kg/m^2^)23.71±2.6024.84±2.74\*Waist circumference (cm)83.82±7.9488.19±7.74\*Hip circumference (cm)96.26±6.9997.54±5.77WHR0.87±0.050.90±0.05\*A1C5.57±0.177.63±0.11\*0-h PG (mmol/L)5.14±0.258.53±0.17\*1/2-h PG (mmol/L)7.13±0.3411.52±0.23\*2-h PG (mmol/L)5.80±0.4613.04±0.31\*0-h INS (mmol/L)7.74±2.049.52±1.241/2-h INS (mmol/L)40.77±3.0413.26±1.88\*2-h INS (mmol/L)32.55±2.9425.36±1.82\*TG (mmol/L)1.48±0.262.34±0.17\*TC (mmol/L)4.69±0.195.16±0.13\*HDL-C (mmol/L)1.13±0.051.21±0.03LDL-C (mmol/L)2.65±0.163.08±0.11\*IL-6 (pg/mL)79.08±12.45129.78±8.16\*TNF-α (pg/mL)17.79±1.9333.06±1.26\*IL-1β (pg/mL)139.22±12.23153.26±8.20IL-2 (pg/mL)92.97±16.58149.16±10.86\*Ferritin (ng/mL)121.31±13.69182.49±11.71\*[^1]

Comparison of the parameters between the acarbose-treated T2DM subgroup and metformin-treated T2DM subgroup {#S0003-S2002}
-----------------------------------------------------------------------------------------------------------

The age and sex distributions were comparable between the two subgroups. Greater waist circumferences and WHR were observed in the metformin subgroup than in the acarbose subgroup (*P*\<0.05). The 0 hr, 1/2 hr, and 2 hr glucose, insulin, A1C, TG, TC, HDL-C, LDL-C, IL-6, TNF-α, IL-1β, IL-2 and ferritin levels at baseline were comparable between the two subgroups ([Table 2](#T0002){ref-type="table"}).Table 2Comparison of the parameters at baseline between the acarbose group and metformin groupParametersMetformin group (n=36)Acarbose group (n=34)Sex (males/females)22/1422/12Age (years)51.31±9.0251.38±9.61BMI (kg/m^2^)25.04±2.6824.64±2.83Waist circumference (cm)90.03±7.6686.25±7.45\*Hip circumference (cm)98.08±5.4896.97±6.09WHR0.92±0.520.89±0.05\*A1C7.74±0.167.53±0.190-h PG (mmol/L)8.42±1.628.62±1.701/2-h PG (mmol/L)11.27±2.2911.64±1.992-h PG (mmol/L)13.01±2.9412.90±2.910-h INS (mmol/L)11.51±2.787.87±0.881/2-h INS (mmol/L)13.34±1.8513.28±1.322-h INS (mmol/L)24.18±2.3626.85±3.2TG (mmol/L)2.58±1.812.12±1.46TC (mmol/L)5.19±1.095.08±1.35HDL-C (mmol/L)1.21±0.251.17±0.25LDL-C (mmol/L)3.08±1.023.06±0.93IL-6 (pg/mL)143.93±102.20115.94±23.59TNF-α (pg/mL)31.21±9.5135.56±12.29IL-1β (pg/mL)161.75±70.26140.35±52.91IL-2 (pg/mL)135.17±44.06159.96±101.59Ferritin (ng/mL)196.51±18.93180.41±19.62[^2]

### Comparison of the levels of glucose, insulin and inflammatory factors in the T2DM group before and after treatment {#S0003-S2002-S3001}

Compared with the baseline, the 0 hr, 1/2 hr, and 2 hr glucose, A1C and TNF-α levels were significantly decreased in the T2DM group after 6 months of acarbose and metformin treatment (*P*\<0.05). Compared with the baseline levels, IL-6 levels were significantly reduced in all patients with T2DM after 12 months of treatment compared with the levels recorded after 6 months of treatment (*P*\<0.05), but significant differences were not observed between the two subgroups (*P*\>0.05) ([Table 3](#T0003){ref-type="table"}).Table 3Comparison of glucose, insulin and inflammatory factors before and after treatmentIndicatorsAcarbose group (n=33)Metformin group (n=30)Total (n=63)Baseline6 months12 monthsBaseline6 months12 monthsBaseline6 months12 months0-h PG (mmol/L)8.64±1.747.35±1.63\*7.23±1.68\*8.39±1.676.95±1.39\*6.90±1.91\*8.51±1.697.15±1.51\*7.06±1.77\*1/2-h PG (mmol/L)11.60±2.018.72±1.85\*8.05±1.93\*11.23±2.209.67±2.33\*9.23±2.09\*11.38±2.119.18±2.12\*8.64±2.07\*2-h PG (mmol/L)12.76±2.749.86±2.96\*8.92±2.02\*13.04±2.8610.83±2.4\*10.45±2.54\*12.85±2.7910.30±2.7\*9.63±2.39\*A1C7.56±0.196.43±0.13\*6.57±0.13\*7.79±0.176.35±0.13\*6.4±0.12\*7.68±0.136.39±0.09\*6.49±0.09\*0-h INS (mmol/L)7.94±0.925.79±0.826.06±0.7112.16±3.116.65±0.667.68±0.9910.05±1.836.22±0.52\*6.87±0.611/2-h INS (mmol/L)12.89±1.318.75±1.03\*10.18±1.3814.07±2.0115.84±2.0916.42±1.7613.48±1.1912.30±1.2413.30±1.182-h INS (mmol/L)26.28±3.3117.57±5.10\*17.11±2.14\*25.35±2.4723.13±2.3328.18±2.9625.82±2.0520.35±2.8\*22.65±1.94TNF-α (pg/mL)35.4±12.528.5±11.5\*28.9±9.2\*30.9±8.826.6±10.1\*27.3±9.5\*33.2±10.927.6±10.7\*28.3±9.4\*IL-6 (pg/mL)114.2±23.3110.8±27.196.2±41.1\*149.0±98.8133.0±68.1113.6±57.1\*130.7±78.8120.9±52.2103.8±50.3\*IL-2 (pg/mL)132.2±46.4134.7±71.2136.8±44.9139.7±44.1132.1±25.0141.1±59.5135.2±45.0132.6±53.2138.1±52.0IL-1β (pg/mL)140.2±58.5127.4±56.1129.9±47.7165.6±71.9145.0±55.2137.1±45.0154.6±66.1137.1±55\*133.6±45.9\*Ferritin (ng/mL)189.9±20.06175.2±21.2162.6±17.2\*207.2±23.5164.4±19.2\*171.4±22.5198.3±15.3169.9±14.2\*166.9±13.9\*[^3]

In the acarbose-treated T2DM subgroup, lower 0 hr, 1/2 hr and 2 hr insulin levels were measured after 6 months than at baseline (*P*\<0.05). After 12 months of treatment, lower 2 hr insulin and ferritin levels were observed than at baseline (*P*\<0.05). In the metformin-treated T2DM subgroup, a significantly lower ferritin level was observed after 6 months of treatment than at baseline (*P*\<0.05). However, a further decrease was not observed after 12 months of treatment. After 6 months or 12 months of treatment, the 0 hr, 1/2 hr and 2 hr insulin levels did not significantly differ from the levels recorded at baseline ([Table 3](#T0003){ref-type="table"}). After 6 months of treatment, the 0 hr, 1/2 hr and 2 hr glucose, IL-1β, TNF-α and ferritin levels were significantly lower than the baseline levels in the T2DM group treated with acarbose or metformin (*P*\<0.05), and the IL-6 level was also significantly decreased after 12 months of treatment (*P*\<0.05) ([Table 3](#T0003){ref-type="table"}).

### Comparison of inflammatory factors in the NC group and T2DM group after 12 months of treatment {#S0003-S2002-S3002}

In the NC group and T2DM group, the age, BMI, waist circumference, and hip circumference were comparable, but sex and WHR differed (*P*\<0.05). After adjusting for sex and WHR, the levels of IL-6, TNF-α, IL-2 and ferritin in the T2DM group were still higher after 12 months than in the NC group (*P*\<0.05), but no significant differences in IL-1β levels were observed between these two groups ([Table 4](#T0004){ref-type="table"}).Table 4Comparison of the inflammation factors in the NC and T2DM groups after 12 months of treatmentIndicatorsNC (n=32)T2DM (n=63)IL-6 (pg/mL)75.62±7.87104.84±5.56\*TNF-α (pg/mL)17.45±1.5128.24±1.13\*IL-1β (pg/mL)137.15±7.91137.25±7.0IL-2 (pg/mL)95.62±8.87139.45±6.27\*Ferritin (ng/mL)114.59±12.03156.17±10.55\*[^4]

### Comparison of the degree of variability in glucose, A1C, insulin, IL-6, IL-2, TNF-α, IL-1β and ferritin levels in the two T2DM subgroups before and after treatment {#S0003-S2002-S3003}

Compared with the metformin subgroup, the 1/2 hr glucose and insulin levels measured in the standard meal test exhibited a more significant decrease after 6 months of treatment and the 1/2 hr and 2 hr glucose and insulin levels measured in the standard meal test were significantly decreased after 12 months of treatment with acarbose (*P*\<0.05). After 6 months or 12 months of treatment, the variation margins of IL-2, IL-6, IL-1β, TNF-α and ferritin levels were similar between individuals treated with the two drugs ([Table 5](#T0005){ref-type="table"}).Table 5Comparison of the variation margin of glucose, insulin and inflammatory factors in the two groupsParametersAfter 6 months of treatmentAfter 12 months of treatmentMetformin groupAcarbose groupMetformin groupAcarbose groupΔ 0-h glu (mmol/L)−1.17±0.35−1.28±0.35−1.26±0.38−1.45±0.38Δ 1/2-h glu (mmol/L)−1.19±0.46−2.86±0.46\*−1.64±0.46−3.48±0.46\*Δ 2-h glu (mmol/L)−1.95±0.49−2.81±0.49−2.28±0.50−3.75±0.50\*Δ A1C−1.45±0.17−1.12±0.17−1.40±0.18−0.98±0.18Δ 0-h ins (mmol/L)−5.25±2.23−2.42±2.23−4.23±2.43−2.14±2.43Δ 1/2-h ins (mmol/L)2.33±1.99−4.69±1.99\*2.69±2.11−3.05±2.11Δ 2-h ins (mmol/L)−2.15±3.32−8.78±3.322.07±3.18−8.41±3.18\*Δ IL-2 (pg/mL)−6.18±12.819.56±12.824.36±12.63−0.23±12.63Δ IL-6 (pg/mL)1.78±9.23−0.26±9.23−31.18±13.2−17.81±13.64Δ IL-1β (pg/mL)−20.72±8.94−13.78±9.73−29.59±12.03−9.28±12.34Δ TNF-α (pg/mL)−4.06±1.45−7.31±1.48−3.07±1.63−5.70±1.67Δ Ferritin (ng/mL)−43.19±9.99−14.35±9.74−34.30±8.84−27.15±8.83[^5]

Discussion {#S0004}
==========

The levels of inﬂammatory biomarkers, such as IL-6, TNF-α and IL-2, are increased in patients with T2DM.[@CIT0002],[@CIT0018] Our study revealed the same results in patients with newly diagnosed T2DM, who exhibited significantly higher IL-6, TNF-α, IL-2 and ferritin levels than the NCs, indicating that T2DM is characterized by a chronic inflammatory state.

Based on accumulating evidence, the inflammatory state is involved in the development of microvascular and macrovascular complications in patients with T2DM.[@CIT0008],[@CIT0019],[@CIT0020] Theoretically, anti-inflammatory therapy can prevent cardiovascular complications and improve the patients' quality of life. Metformin, a basic, widely used hypoglycemic agent, has been found to reduce the levels of two major inflammatory biomarkers, ie, CRP and TNF-α.[@CIT0010],[@CIT0011] Compared with a placebo, acarbose decreases the concentrations of IL-6 and TNF-α.[@CIT0015],[@CIT0021] However, no studies investigated the effects of long-term treatment with metformin or acarbose on the levels of three other major inflammatory cytokines, IL-1β, IL-2 and ferritin, or compared the effects of these two drugs on the levels of inflammatory biomarkers.[@CIT0022] In this prospective randomized controlled study, compared to the baseline, the IL-6, TNF-α and ferritin levels were significantly decreased in the T2DM group after treatment, suggesting that acarbose and metformin both improved the chronic inflammatory state in patients with T2DM. Additional long-term, large-scale clinical trials are needed to determine whether these treatments prevent the development of complications.

Metformin may exert its anti-inflammatory effects by activating AMP-activated protein kinase, antioxidant activity, and insulin sensitization.[@CIT0023]--[@CIT0025] Acarbose can indirectly improve insulin resistance.[@CIT0015],[@CIT0019],[@CIT0026] As shown in the study by Fukaya N, et al, the alpha-glucosidase inhibitor miglitol reduces the hyperglycemia-induced mRNA expression of inflammatory cytokines in peripheral blood leukocytes.[@CIT0027] However, researchers have not clearly determined whether the anti-inflammatory mechanisms of metformin and acarbose rely on indirect effects, such as improving insulin sensitivity and reducing glucose, or direct anti-inflammatory effects. In the present study, the TNF-α and ferritin levels decreased significantly after 6 months of treatment with metformin, while ferritin levels decreased at 12 months after treatment with acarbose, indicating these two drugs may improve inflammation through different mechanisms. Considering their distinct hypoglycemic and anti-inflammatory mechanisms, we speculated that a combination therapy including metformin and acarbose may exert a synergistic effect on inflammation.

The changes in the levels of these inflammatory cytokines were different in our study. TNF-α and IL-1β levels were significantly decreased in all patients with newly diagnosed T2DM after 6 months of treatment, and the IL-2, IL-6, and ferritin levels only showed a decreasing trend. After 12 months of treatment, the IL-6 levels were significantly reduced. Based on these results, a separate analysis of IL-1β levels in the metformin and acarbose subgroups was performed, and a significant reduction was not observed after treatment. Based on these results, the chronic inflammatory status was not improved as quickly as glucose metabolism and required a long-lasting therapy. Further research is needed to determine the duration of treatment required take to significantly improve the inflammatory status.

Furthermore, even after one year of hypoglycemic treatment and good glucose control, the patients still presented higher levels of these inflammatory cytokines than the NC group, suggesting that the inflammatory state in patients with T2DM was severe and persistent. Further study should consider whether direct anti-inflammatory drugs should be administered in the early therapeutic regimen, even in patients with newly diagnosed T2DM.

Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), has been reported to inhibit the rolling and adhesion of T cells induced by TNF-α and reduce the levels of cytokines and other inflammatory markers, such as CRP and IL-6,[@CIT0028]--[@CIT0030] Statins significantly reduce the levels of inflammatory factors independent of their effects on lipids.[@CIT0031],[@CIT0032]Angiotensin-converting enzyme inhibitors (ACEIs) and adrenergic receptor-binding agents (ARBs) might exert anti-inflammatory effects since angiotensin II is a precursor inflammatory peptide, and ARBs inhibit the generation of oxygen species and inflammatory mediators.[@CIT0033],[@CIT0034] Two large studies investigating cardiovascular events as endpoints showed that ramipril and losartan reduce the incidence of T2DM, potentially due to their anti-inflammatory effects.[@CIT0035],[@CIT0036] In addition, the inflammatory factor inhibitors, including a TNF-α inhibitor (infliximab) and interleukin-1 receptor antagonist (IL-1Ra), have been confirmed to exert both anti-inflammatory and hypoglycemic effects on an animal model of T2DM.[@CIT0003],[@CIT0037],[@CIT0038] However, aspirin applications are limited since the absolute benefits in reducing risk of vascular complications in patients with diabetes who do not present an evident cardiovascular disease are largely counterbalanced by the risk of bleeding.[@CIT0033] Additionally, the administration of statins, ACEIs and ARBs should depend on the patient's blood lipid levels and blood pressure. Further studies are needed to determine whether these drugs are able to be used earlier to control the chronic inflammatory state and prevent the development of chronic complications of diabetes.

This study has several limitations. First, the sample size was a bit small. Second, this study did not include a placebo control group due to ethical considerations. Finally, the treatment duration was one year, and we did not clearly determine whether the effect of a subsequent longer term treatment on the levels of inflammatory factors reduced vascular complications.

In summary, the IL-6, TNF-α, IL-2 and ferritin levels were significantly increased in patients with newly diagnosed T2DM. One year of treatment with metformin or acarbose significantly improved the blood glucose levels and reduced the levels of these inflammatory factors. However, the anti-inflammatory effects of metformin and acarbose differed. Additionally, the anti-inflammatory effects of these two hypoglycemic drugs were only detected after a long-term treatment (1 year). These results must be confirmed and clarified in additional large-sample prospective studies.
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The Metformin and Acarbose in Chinese as the initial Hypoglycemic treatment (MARCH) Study (Registry number: ChiCTR-TRC-08000231) compared the medical outcomes of two different glycemic treatment approaches. This study was a non-inferiority, multicenter randomized controlled trial that tested two drug interventions (metformin and acarbose). Our study was performed at one of the 11 clinical sites in China invited to participate, which had received ethical approval. All trial participants who were enrolled in the present study provided written informed consent (no additional registration of RCT), and the study was performed in accordance with the principles of the Declaration of Helsinki.

Disclosure {#S0006}
==========

The authors report no conflicts of interest in this work.

[^1]: **Note:** \**P*\<0.05 compared with the NC group.

    **Abbreviations:** NC, normal control; T2DM, type 2 diabetes; BMI, body mass index; WHR, waist-to-hip ratio; A1C, glycosylated hemoglobin; 0-h PG, 0-hour postprandial glucosein the standard meal test; 1/2-h PG, 1/2-hour postprandial glucose in the standard meal test; 2-h PG, 2-hour postprandial glucose in the standard meal test; 0-h INS, 0-hour insulin in the standard meal test; 1/2-h INS, 1/2-hour insulin in the standard meal test; 2-h INS, 2-hour insulin in the standard meal test; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IL-6, inflammatory biomarker levels; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-2, interleukin-2.

[^2]: **Note:** \**P*\<0.05 compared with the metformin group.

    **Abbreviations:** BMI, body mass index; WHR, waist-to-hip ratio; A1C, glycosylated hemoglobin; 0-h PG, 0-hour postprandial glucosein the standard meal test; 1/2-h PG, 1/2-hour postprandial glucose in the standard meal test; 2-h PG, 2-hour postprandial glucose in the standard meal test; 0-h INS, 0-hour insulin in the standard meal test; 1/2-h INS, 1/2-hour insulin in the standard meal test; 2-h INS, 2-hour insulin in the standard meal test; TG: triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IL-6, inflammatory biomarker levels; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-2, interleukin-2.

[^3]: **Note:** \**P*\<0.05 compared with baseline.

    **Abbreviations:** 0-h PG, 0-hour postprandial glucosein the standard meal test; 1/2-h PG, 1/2-hour postprandial glucose in the standard meal test; 2-h PG, 2-hour postprandial glucose in the standard meal test; A1C, glycosylated hemoglobin;0-h INS, 0-hour insulin in the standard meal test; 1/2-h INS, 1/2-hour insulin in the standard meal test; 2-h INS, 2-hour insulin in the standard meal test; TNF-α, tumor necrosis factor-α; IL-6, inflammatory biomarker levels; IL-2, interleukin-2; IL-1β, interleukin-1β.

[^4]: **Note:** \**P*\<0.05 compared with the NC group.

    **Abbreviations:** NC, normal control; T2DM, type 2 diabetes; IL-6, inflammatory biomarker levels; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-2, interleukin-2.

[^5]: **Note:** \**P*\<0.05 compared with the metformin group. Δglu 0h: 0 hr glucose in the standard meal test after treatment - 0 hr glucose in the standard meal test before treatment; Δglu1/2h: 1/2 hr glucose in the standard meal test after treatment - 1/2 hr glucose in the standard meal test before treatment; Δglu2h: 2 hr glucose in the standard meal test after treatment - 2 hr glucose in the standard meal test before treatment; ΔA1c: A1c after treatment - A1c before treatment; Δins0h: 0 hr insulin in the standard meal test after treatment - 0 hr insulin in the standard meal test before treatment; Δins1/2h: 1/2 hr insulin in the standard meal test after treatment - 1/2 hr insulin in the standard meal test before treatment; Δins2h: 2 hr insulin in the standard meal test after treatment - 2 hr insulin in the standard meal test before treatment; ΔIL-2: IL-2 after treatment - IL-2 before treatment; ΔIL-6: IL-6 after treatment - IL-6 before treatment; ΔIL-1β: IL-1β after treatment - IL-1β before treatment; ΔTNF-α: TNF-α after treatment - TNF-α before treatment; and ΔFerritin: ferritin after treatment -- ferritin before treatment.
